069620 — Daewoong Pharma Balance Sheet
0.000.00%
- KR₩1tn
- KR₩2tn
- KR₩1tn
- 63
- 29
- 78
- 61
Annual balance sheet for Daewoong Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 177,120 | 173,734 | 140,651 | 137,685 | 116,347 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 147,652 | 159,635 | 179,243 | 177,954 | 212,456 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 528,351 | 520,401 | 548,968 | 574,824 | 612,792 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 393,690 | 395,866 | 440,890 | 521,919 | 675,666 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,366,908 | 1,410,687 | 1,563,341 | 1,770,311 | 1,976,977 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 326,750 | 460,660 | 472,831 | 667,117 | 629,416 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 815,914 | 841,156 | 955,323 | 1,003,008 | 1,182,403 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 550,994 | 569,531 | 608,017 | 767,303 | 794,574 |
Total Liabilities & Shareholders' Equity | 1,366,908 | 1,410,687 | 1,563,341 | 1,770,311 | 1,976,977 |
Total Common Shares Outstanding |